ACCP Annual Meeting Invited Keynote

Alex Zhavoronkov, PhD – Founder & Chief Executive Officer, Insilico Medicine Inc 
Machine Learning: Will We Still Need Clinical Pharmacologists in the Next Decade?

Alex Zhavoronkov, PhD, is the Founder & Chief Executive Officer of Insilico Medicine Inc, a leader in next-generation artificial intelligence technologies for drug discovery, biomarker development and aging research. At Insilico, Dr. Zhavoronkov pioneered the applications of generative adversarial networks and reinforcement learning for generating novel molecular structures with the desired properties and generation of synthetic biological and patient data. He was the first to develop deep multi-modal predictors of age using multiple data types. He set up R&D centers in countries including the United Kingdom, Korea, Russia, Hong Kong and Taiwan and launched multiple digital biomarker initiatives including Young.AI.

Prior to founding Insilico Medicine Inc, Dr. Zhavoronkov worked in senior roles at ATI Technologies Inc (acquired by Advanced Micro Devices Inc in 2006), NeuroG Neuroinformatics and YLabs.AI and he established competitions and the  Diversity.AI initiative. He is the Co-founder & Chief Science Officer (CSO) of the Biogerontology Research Foundation, a registered UK charity focusing on age-related diseases.

Since 2012, Dr. Zhavoronkov has published over 130 peer-reviewed research papers and two books, including The Ageless Generation: How Biomedical Advances Will Transform the Global Economy. From 2014 to 2018, he presented at over 200 academic and industry conferences. He serves on the editorial boards of some of the highest-impact journals in the field including Aging, Aging Research Reviews and Frontiers in Genetics of Aging. He also chairs the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence for Healthcare Forum at Basel Life, one of Europe’s largest industry events in drug discovery.